Cargando…

Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data

OBJECTIVES: A review of patients requiring lifelong antibiotics to control, rather than cure, infection was performed [‘palliative outpatient parenteral antibiotic therapy (OPAT)’]. This was to evaluate emerging themes and complications. The aim was to aid in the management of such patients. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Hart, Elizabeth, Snape, Sue, Thomson, Ross
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210122/
https://www.ncbi.nlm.nih.gov/pubmed/34223011
http://dx.doi.org/10.1093/jacamr/dlaa052
_version_ 1783709248625049600
author Hart, Elizabeth
Snape, Sue
Thomson, Ross
author_facet Hart, Elizabeth
Snape, Sue
Thomson, Ross
author_sort Hart, Elizabeth
collection PubMed
description OBJECTIVES: A review of patients requiring lifelong antibiotics to control, rather than cure, infection was performed [‘palliative outpatient parenteral antibiotic therapy (OPAT)’]. This was to evaluate emerging themes and complications. The aim was to aid in the management of such patients. METHODS: A retrospective review of the OPAT database over 5 years (2013–17) was performed. Of the 1438 patients, 9 were deemed to have received palliative OPAT. RESULTS: The palliative cohort represented 0.6% of the total number of patients on OPAT and 8.6% of the bed days saved. Patients fell into two main groups: those with multiple comorbidities that precluded surgical management and those with a terminal condition. Both groups received IV antibiotics with no clear endpoint. The themes to emerge were: patients often had multiple comorbidities with a high operative risk to control the source of infection; a trial of no or oral antibiotics led to resurgence of the infection; vascular patients appeared to tolerate long-term antibiotics well; and conversely, antibiotic side effects were a significant issue in others. Patients with incurable cancer and a coincident infection can be given additional quality of life with the judicious use of appropriate therapy. CONCLUSIONS: There are significant issues surrounding antimicrobial stewardship in the palliative OPAT group that should be considered. Excellent communication is required to deal with these often very complicated patients. There are considerable gains to be made both for patients and the number of bed days saved. The small number of patients accounted for a disproportionate number of bed days saved.
format Online
Article
Text
id pubmed-8210122
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-82101222021-07-02 Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data Hart, Elizabeth Snape, Sue Thomson, Ross JAC Antimicrob Resist Original Article OBJECTIVES: A review of patients requiring lifelong antibiotics to control, rather than cure, infection was performed [‘palliative outpatient parenteral antibiotic therapy (OPAT)’]. This was to evaluate emerging themes and complications. The aim was to aid in the management of such patients. METHODS: A retrospective review of the OPAT database over 5 years (2013–17) was performed. Of the 1438 patients, 9 were deemed to have received palliative OPAT. RESULTS: The palliative cohort represented 0.6% of the total number of patients on OPAT and 8.6% of the bed days saved. Patients fell into two main groups: those with multiple comorbidities that precluded surgical management and those with a terminal condition. Both groups received IV antibiotics with no clear endpoint. The themes to emerge were: patients often had multiple comorbidities with a high operative risk to control the source of infection; a trial of no or oral antibiotics led to resurgence of the infection; vascular patients appeared to tolerate long-term antibiotics well; and conversely, antibiotic side effects were a significant issue in others. Patients with incurable cancer and a coincident infection can be given additional quality of life with the judicious use of appropriate therapy. CONCLUSIONS: There are significant issues surrounding antimicrobial stewardship in the palliative OPAT group that should be considered. Excellent communication is required to deal with these often very complicated patients. There are considerable gains to be made both for patients and the number of bed days saved. The small number of patients accounted for a disproportionate number of bed days saved. Oxford University Press 2020-08-06 /pmc/articles/PMC8210122/ /pubmed/34223011 http://dx.doi.org/10.1093/jacamr/dlaa052 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hart, Elizabeth
Snape, Sue
Thomson, Ross
Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title_full Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title_fullStr Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title_full_unstemmed Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title_short Palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
title_sort palliative outpatient parenteral antibiotic therapy: a review of 5 years of patient data
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210122/
https://www.ncbi.nlm.nih.gov/pubmed/34223011
http://dx.doi.org/10.1093/jacamr/dlaa052
work_keys_str_mv AT hartelizabeth palliativeoutpatientparenteralantibiotictherapyareviewof5yearsofpatientdata
AT snapesue palliativeoutpatientparenteralantibiotictherapyareviewof5yearsofpatientdata
AT thomsonross palliativeoutpatientparenteralantibiotictherapyareviewof5yearsofpatientdata